Evidence map›Paper›PMID 38005401›Full record

ReviewMolecules (Basel, Switzerland)2023

Joining Forces: The Combined Application of Therapeutic Viruses and Nanomaterials in Cancer Therapy.

Hongyu Li, Yunhuan Zhu, Xin Wang, Yilu Feng, Yuncheng Qian, Qiman Ma, Xinyuan Li, Yihan Chen, Keda Chen

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Oncolytic virotherapy and tumor microenvironment modulation.Clinical and experimental medicine · 2025
    Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hongyu LiShulan International Medical College, Zhejiang Shuren University, Hangzhou 310015, China.ORCID 0009-0003-0594-2478
Yunhuan ZhuShulan International Medical College, Zhejiang Shuren University, Hangzhou 310015, China.
Xin WangCenter of Infectious Disease Research, School of Life Science, Westlake University, Hangzhou 310024, China.
Yilu FengShulan International Medical College, Zhejiang Shuren University, Hangzhou 310015, China.
Yuncheng QianShulan International Medical College, Zhejiang Shuren University, Hangzhou 310015, China.
Qiman MaShulan International Medical College, Zhejiang Shuren University, Hangzhou 310015, China.
Xinyuan LiShulan International Medical College, Zhejiang Shuren University, Hangzhou 310015, China.
Yihan ChenShulan International Medical College, Zhejiang Shuren University, Hangzhou 310015, China.
Keda ChenShulan International Medical College, Zhejiang Shuren University, Hangzhou 310015, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer, on a global scale, presents a monumental challenge to our healthcare systems, posing a significant threat to human health. Despite the considerable progress we have made in the diagnosis and treatment of cancer, realizing precision cancer therapy, reducing side effects, and enhancing efficacy remain daunting tasks. Fortunately, the emergence of therapeutic viruses and nanomaterials provides new possibilities for tackling these issues. Therapeutic viruses possess the ability to accurately locate and attack tumor cells, while nanomaterials serve as efficient drug carriers, delivering medication precisely to tumor tissues. The synergy of these two elements has led to a novel approach to cancer treatment-the combination of therapeutic viruses and nanomaterials. This advantageous combination has overcome the limitations associated with the side effects of oncolytic viruses and the insufficient tumoricidal capacity of nanomedicines, enabling the oncolytic viruses to more effectively breach the tumor's immune barrier. It focuses on the lesion site and even allows for real-time monitoring of the distribution of therapeutic viruses and drug release, achieving a synergistic effect. This article comprehensively explores the application of therapeutic viruses and nanomaterials in tumor treatment, dissecting their working mechanisms, and integrating the latest scientific advancements to predict future development trends. This approach, which combines viral therapy with the application of nanomaterials, represents an innovative and more effective treatment strategy, offering new perspectives in the field of tumor therapy.

Indexed as

NanostructuresNeoplasmsOncolytic VirotherapyOncolytic VirusesDrug CarriersHumansDrug Carrierscombined applicationdrug carriersnanomaterialstherapeutic virusestumor treatment

Identifiers

PMID38005401
PMCPMC10674375

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.